HighTide Therapeutics Inc
Company Profile
Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Ganli Second Road
18B-102, Zhonghaixin Innovation Industry City
Jihua Neighborhood
Longgang District, Guangdong
Shenzhen518112
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
68
Stocks News & Analysis
stocks
2 undervalued ASX shares report
stocks
Turmoil at WiseTech
video
What does the RBA rate cut mean for investors?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,494.50 | 65.60 | -0.77% |
CAC 40 | 8,090.99 | 63.52 | -0.78% |
DAX 40 | 22,425.93 | 138.37 | 0.62% |
Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
FTSE 100 | 8,658.98 | 0.39 | -0.00% |
HKSE | 22,998.69 | 342.92 | -1.47% |
NASDAQ | 19,286.93 | 237.08 | -1.21% |
Nikkei 225 | 38,345.99 | 430.95 | -1.11% |
NZX 50 Index | 12,355.74 | 175.98 | -1.40% |
S&P 500 | 5,983.25 | 29.88 | -0.50% |
S&P/ASX 200 | 8,247.00 | 61.20 | -0.74% |
SSE Composite Index | 3,359.27 | 13.76 | -0.41% |